IPSEN (OTCMKTS:IPSEY) Share Price Passes Above 200-Day Moving Average – Should You Sell?

IPSEN (OTCMKTS:IPSEY) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $33.57 and traded as high as $34.93. IPSEN shares last traded at $34.93, with a volume of 1,301 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a report on Monday, November 3rd. BNP Paribas lowered shares of IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, IPSEN has a consensus rating of “Hold”.

IPSEN Stock Performance

The company has a 50-day simple moving average of $35.87 and a 200-day simple moving average of $33.59.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).